Liquidia Corporation (LQDA)
NASDAQ: LQDA · Real-Time Price · USD
14.54
-0.06 (-0.41%)
At close: Jul 18, 2025, 4:00 PM
14.58
+0.04 (0.28%)
After-hours: Jul 18, 2025, 7:58 PM EDT
Liquidia Revenue
Liquidia had revenue of $3.12M in the quarter ending March 31, 2025, with 4.98% growth. This brings the company's revenue in the last twelve months to $14.14M, down -11.42% year-over-year. In the year 2024, Liquidia had annual revenue of $14.00M, down -19.97%.
Revenue (ttm)
$14.14M
Revenue Growth
-11.42%
P/S Ratio
83.42
Revenue / Employee
$83,200
Employees
170
Market Cap
1.24B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LQDA News
- 20 days ago - What Next For Liquidia After Launch? - Seeking Alpha
- 27 days ago - Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ - GlobeNewsWire
- 6 weeks ago - Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - GlobeNewsWire
- 7 weeks ago - These Analysts Boost Their Forecasts On Liquidia - Benzinga
- 7 weeks ago - Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire
- 2 months ago - Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - GlobeNewsWire
- 2 months ago - Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript - Seeking Alpha